

Last Close <b>4.91 (EUR)</b>	Avg Daily Vol <b>297,082</b>	52-Week High <b>5.78</b>	Trailing PE --	Annual Div --	ROE <b>-26.3%</b>	LTG Forecast --	1-Mo Return <b>-8.4%</b>
2017 May 19 BRUSSELS Exchange	Market Cap <b>245M</b>	52-Week Low <b>2.87</b>	Forward PE --	Dividend Yield --	Annual Rev <b>27M</b>	Inst Own <b>22.3%</b>	3-Mo Return <b>-8.3%</b>


**AVERAGE SCORE**

**AVERAGE SCORE**  
**4**

**NEUTRAL OUTLOOK:** MDXH's current score is relatively in-line with the market.

**Score Averages**

Biotech & Med. Research Group:	<b>3.0</b>	Mid/Small Market Cap:	<b>5.4</b>
Pharma. & Med. Research Sector:	<b>3.1</b>	BEL 20 Index:	<b>5.1</b>



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
CYAD	1	1	4	4	<b>6</b>	
ABLX	2	5	4	4	<b>4</b>	
<b>MDXH</b>	<b>7</b>	<b>7</b>	<b>3</b>	<b>3</b>	<b>4</b>	
ARGX	6	4	4	2	<b>2</b>	
THR	1	2	1	1	<b>1</b>	

**HIGHLIGHTS**


- The score for MDxHealth improved slightly this week from 3 to 4.
- The recent change in the Average Score was primarily due to an improvement in the Fundamental and Relative Valuation component scores.

**THOMSON REUTERS I/B/E/S MEAN**

**Strong Buy**

2 Analysts



Mean recommendation from all analysts covering the company on a standardized 5-point scale.



**PRICE AND VOLUME CHARTS**

**1-Year Return: 49.7%**

**5-Year Return: 227.3%**



**BUSINESS SUMMARY**

MDxHealth SA is a Belgium-based multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.




INDICATOR COMPONENTS

AVERAGE SCORE

4

The **AVERAGE SCORE** combines the quantitative analysis of five widely-used investment decision making tools: Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.



PEER ANALYSIS

Currency in EUR

Average Score	Ticker	PRICE MOMENTUM				VALUATION		FUNDAMENTAL		ANALYSTS		# of Analysts	
		Price (2017-05-19)	1-Mo Return	3-Mo Return	1-Yr Return	Market Cap	Trailing PE	Forward PE	Dividend Yield	Net Margin	LTG Forecast		I/B/E/S Mean
5	UCB	76.59	6.5%	12.5%	16.2%	14.9B	27.8	20.9	1.1%	12.4%	17.0%	Buy	16
4	FAGR	11.65	-7.2%	17.5%	79.1%	837M	--	19.1	--	-4.9%	--	Buy	3
4	ABLX	11.01	5.7%	-11.7%	-21.4%	673M	--	--	--	-1.3%	--	Buy	6
2	ARGX	19.15	15.1%	25.2%	65.2%	353M	--	--	--	-140.0%	--	Strong Buy	4
6	CYAD	36.96	40.9%	95.0%	-16.1%	352M	--	--	--	-277.0%	--	Buy	5
2	MITRA	9.08	-2.5%	-15.2%	0.0%	283M	--	--	--	-156.2%	--	Buy	2
4	MDXH	4.91	-8.4%	-8.3%	49.7%	245M	--	--	--	-44.0%	--	Strong Buy	2
4	TIG	0.77	2.9%	10.4%	-15.6%	201M	38.7	--	--	15.0%	--	Strong Buy	1
1	THR	3.21	10.4%	-6.4%	-1.5%	116M	--	--	--	-849.0%	--	Hold	1
2	BOTHE	6.93	-6.3%	-11.3%	-62.5%	47M	--	--	--	--	--	Buy	2
NR	PHAR	0.29	-12.1%	-47.3%	-42.0%	--	--	--	533.7%	--	--	--	--
3.4	Average	16.41	4.1%	5.5%	4.6%	1.6B	33.2	20.0	267.4%	-160.5%	17.0%	Buy	4.2

PEER COMPANIES

UCB	UCB	MITRA	Mithra Pharmaceuticals
FAGR	Fagron	TIG	Tigenix
ABLX	Ablynx	THR	ThromboGenics
ARGX	argenx	BOTHE	Bone Therapeutics
CYAD	Celyad	PHAR	Pharco



**EARNINGS**

EARNINGS

**8**


Currency in EUR

**POSITIVE OUTLOOK:** Strong earnings with recent analyst upgrades or a history of surpassing consensus estimates.

**Earnings Score Averages**

Biotech & Med. Research Group: **4.1**      Mid/Small Market Cap: **5.4**  
Pharma. & Med. Research Sector: **4.4**      BEL 20 Index: **4.3**

**Earnings Score Trend (4-Week Moving Avg)**




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
CYAD	1	3	3	5	<b>8</b>	
<b>MDXH</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>9</b>	<b>8</b>	
ABLX	2	3	8	7	<b>7</b>	
THR	1	2	1	2	<b>2</b>	
ARGX	10	7	3	1	<b>1</b>	

**EARNINGS INDICATORS**

**Earnings Surprises**  
(33.3% weight)

**Estimate Revisions**  
(33.3% weight)

**Recommendation Changes**  
(33.3% weight)



**Last 4 Years**

# Positive Surprises (> 2%)	3
# Negative Surprises (< -2%)	1
# In-Line Surprises (within 2%)	0
Avg Surprise	5.6%

**Last 4 Weeks**

# Up Revisions	1
# Down Revisions	0
Avg Up Revisions	50.0%
Avg Down Revisions	0.0%

**Last 120 Days**

# Broker Upgrades	0
# Broker Downgrades	0

**HIGHLIGHTS**

- MDxHealth currently has an Earnings Rating of 8, which is significantly more bullish than the Biotech & Med Research industry average of 5.3.
- There have been no upward or downward broker recommendation changes for MDxHealth over the past 120 days.

**PRICE TARGET**

The chart indicates where analysts predict the stock price will be within the next 12 months, as compared to the current price.



**12-Month Price Target**


Mean	6.50
High	6.50
Low	6.50
Target vs. Current	32.4%
# of Analysts	2




EARNINGS PER SHARE

Earnings per share (EPS) is calculated by dividing a company's earnings by the number of shares outstanding. Analysts tend to interpret a pattern of increasing earnings as a sign of strength and flat or falling earnings as a sign of weakness.

The charts provide a comparison between a company's actual and estimated EPS, including the high and low forecasts.



Quarterly	NA	NA
Mean	--	--
High	--	--
Low	--	--
# of Analysts	--	--



Annual	2017	2018
Mean	-0.023	0.101
High	0.092	0.221
Low	-0.138	-0.018
# of Analysts	2	2

MEAN ESTIMATE TREND

	Q	Q	Y	Y	Price Target
	--	--	2017	2018	
Current	--	--	-0.023	0.101	6.50
30 Days Ago	--	--	-0.097	0.134	6.67
90 Days Ago	--	--	-0.152	0.258	6.75
% Change (90 Days)	--	--	84.9%	-60.9%	-3.7%

Current Fiscal Year End: 17-12  
Next Expected Report Date: 2017-08-21

ANALYST RECOMMENDATIONS

Thomson Reuters I/B/E/S Mean: **Strong Buy** (2 Analysts)

Strong Buy	1
Buy	1
Hold	0
Reduce	0
Sell	0

EARNINGS SURPRISES

Comparing a company's actual earnings to the mean expectation of analysts results in a difference referred to as a 'positive' or 'negative' surprise. Research has shown that when a company reports a surprise, it is often followed by more of the same surprise type.

Surprise Summary (Last 6 Years)


Surprise Type	Amount	Percent
Positive Years (> 2%)	5	83.3%
Negative Years (< -2%)	1	16.7%
In-Line Years (within 2%)	0	--

Surprise Detail (Last 6 Periods)

Surprise Type	Announce Date	Period End Date	Actual EPS	Mean EPS	Surprise (%)
Positive	2017-02-23	2016-12-31	-0.260	-0.277	6.1%
Negative	2016-02-18	2015-12-31	-0.350	-0.296	-18.2%
Positive	2015-02-26	2014-12-31	-0.301	-0.416	27.6%
Positive	2014-02-27	2013-12-31	-0.354	-0.380	6.8%
Positive	2013-02-28	2012-12-31	-0.350	-0.390	10.3%
Positive	2012-03-15	2011-12-31	-0.400	-0.450	11.1%

ANNUAL REVENUE


A pattern of increasing sales in conjunction with a rising EPS may influence a buy recommendation, while flat or falling sales and faltering earnings may explain a sell recommendation. A rising EPS with flat or falling sales may result from increased cost efficiency and margins, rather than market expansion. This chart shows the sales forecast trend of all analysts and the highest and lowest projections for the current and next fiscal year.



	2017	2018
Mean	46.7M	60.1M
High	51.6M	63.1M
Low	41.9M	57.1M
Forecasted Growth	55.9%	100.5%
# of Analysts	2	2




FUNDAMENTAL



**NEUTRAL OUTLOOK:** Fundamentals relatively in-line with the market.


Fundamental Score Averages

Biotech & Med. Research Group:	6.0	Mid/Small Market Cap:	5.7
Pharma. & Med. Research Sector:	5.3	BEL 20 Index:	3.6



Peers	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Current	3Y Trend
ABLX	2	1	1	NR	6	
CYAD	NR	NR	NR	NR	6	
<b>MDXH</b>	<b>3</b>	<b>3</b>	<b>4</b>	<b>NR</b>	<b>6</b>	
ARGX	7	7	7	NR	5	
THR	NR	NR	NR	NR	3	

FUNDAMENTAL INDICATORS



<b>Revenue Growth</b>	69.8%	<b>Current Ratio</b>	4.1	<b>Oper. Cash Yield</b>	-0.3%	<b>Dividend Growth</b>	0.0%
For year over year ending 2016-12		For interim period ending 2016-12		For latest 12 months ending 2016-12		For year over year ending 2016-12	
<b>Gross Margin</b>	55.6%	<b>Debt-to-Capital</b>	0.2%	<b>Accruals</b>	-0.1%	<b>Dividend Payout</b>	0.0%
For latest 12 months ending 2016-12		For annual period ending 2016-12		For latest 12 months ending 2016-12		For latest 12 months ending 2016-12	
<b>Return On Equity</b>	-26.3%	<b>Interest Funding</b>	-3.1%	<b>Days Sales In Inv.</b>	47.2	<b>Dividend Coverage</b>	--
For interim period ending 2016-12		For interim period ending 2016-12		For annual period ending 2016-12		For annual period ending --	
<b>Net Margin</b>	-44.0%	<b>Interest Coverage</b>	-16.1	<b>Days Sales In Rec.</b>	187.8	<b>Current Div. Yield</b>	--
For latest 12 months ending 2016-12		For interim period ending 2016-12		For annual period ending 2016-12		For latest 12 months ending 2017-05	

HIGHLIGHTS

- The Fundamental Rating for MDxHealth improved significantly over the last quarter from a bearish 3 to a relatively neutral 6. The average Fundamental Rating for its Biotech & Med. Research industry group is 6.0 and the BELGIUM 20 index average is 4.8.
- MDXH's gross margin of 55.6% is substantially below the Biotech & Med. Research industry group average of 87.4%.
- MDXH's debt-to-capital of 0.2% is substantially below the Biotech & Med. Research industry group average of 9.7%.
- The company's operating cash yield has been lower than its industry group average for each of the past five years.
- MDxHealth does not currently pay a dividend. Of 6 firms within the Biotech & Med. Research industry group, it is among the 6 companies without a dividend.




**RELATIVE VALUATION**



**NEUTRAL OUTLOOK:** Multiples relatively in-line with the market.

**Relative Valuation Score Averages**

Biotech & Med. Research Group:	<b>3.0</b>	Mid/Small Market Cap:	<b>5.5</b>
Pharma. & Med. Research Sector:	<b>3.3</b>	BEL 20 Index:	<b>4.6</b>




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
ABLX	5	5	5	5	<b>5</b>	
<b>MDXH</b>	<b>4</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>4</b>	
ARGX	4	3	3	3	<b>3</b>	
CYAD	3	2	2	2	<b>2</b>	
THR	5	4	2	2	<b>2</b>	

**RELATIVE VALUATION INDICATORS**

**Forward PEG**  
(50% weight)

**Trailing PE**  
(25% weight)

**Forward PE**  
(25% weight)



Price to Sales	13.5	Trailing PE	--	Forward PE	--
5-Yr Average	14.6	5-Yr Average	--	5-Yr Average	--
Rel. to 5-Yr Avg.	<b>8% Discount</b>	Rel. to 5-Yr Avg.	--	Rel. to 5-Yr Avg.	--
BEL 20 Index	2.0	BEL 20 Index	28.8	BEL 20 Index	18.4
Rel. to BEL 20	<b>&gt;100% Premium</b>	Rel. to BEL 20	--	Rel. to BEL 20	--

**HIGHLIGHTS**


- MDxHealth currently has a Relative Valuation Rating of 4 which is significantly below the BELGIUM 20 index average rating of 5.5.
- MDXH's Price to Sales ratio of 13.5 represents a 8% Discount to its 5-year average of 14.6.



**PRICE TO SALES**

The most recent week's close price divided by the revenue per share.


Price to Sales: 13.5  
5-Year Average: 14.6  
BEL 20 Index Average: 2.0  
Biotech & Med. Research Group Average: 12.6



**TRAILING PE**

The most recent week's close price divided by the sum of the four most recently reported quarterly earnings.


Trailing PE: --  
5-Year Average: --  
BEL 20 Index Average: 28.8  
Biotech & Med. Research Group Average: --



**FORWARD PE**

The most recent week's close price divided by the sum of the four upcoming quarterly consensus estimates.


Forward PE: --  
5-Year Average: --  
BEL 20 Index Average: 18.4  
Biotech & Med. Research Group Average: --



**FORWARD PEG**

The Forward P/E divided by the five-year forecasted growth rate.

Forward PEG: --  
5-Year Average: --  
BEL 20 Index Average: 0.8  
Biotech & Med. Research Group Average: --




RISK

**RISK**  
**2**

**NEGATIVE OUTLOOK:** Variable return patterns (high volatility).

Risk Score Averages

Biotech & Med. Research Group:	2.1	Mid/Small Market Cap:	5.2
Pharma. & Med. Research Sector:	2.2	BEL 20 Index:	6.8



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
CYAD	3	4	5	4	4	
THR	3	2	3	4	4	
ABLX	1	2	3	3	3	
<b>MDXH</b>	<b>3</b>	<b>4</b>	<b>3</b>	<b>2</b>	<b>2</b>	
ARGX	4	3	3	5	1	


RISK INDICATORS

Magnitude Of Returns (25% weight)

Volatility (25% weight)

Beta (1-year) (25% weight)

Correlation (25% weight)



Daily Returns (Last 90 Days)		Standard Deviation		Beta vs. BEL 20		Correlation vs. BEL 20	
Best	5.0%	Last 90 Days	1.94	Positive Days Only	0.67	Last 90 Days	30%
Worst	-5.6%	Last 60 Months	9.84	Negative Days Only	0.55	Last 60 Months	25%
Monthly Returns (Last 60 Months)		Intra-Day Swing (Last 90 Days)		Beta vs. Group		Correlation vs. Group	
Best	25.4%	Average	3.0%	Positive Days Only	0.69	Last 90 Days	28%
Worst	-21.2%	Largest	9.2%	Negative Days Only	0.28	Last 60 Months	34%

HIGHLIGHTS

- MDxHealth currently has a Risk Rating of 2, which is significantly below the BELGIUM 20 index average rating of 6.7.
- On days when the market is up, MDXH shares tend to lag the BELGIUM 20 index. However, on days when the market is down, the shares generally decrease less than the index.
- In both short-term and long-term periods, MDXH has shown average correlation (> 0.2 and < 0.4) with the BELGIUM 20 index. Thus, this stock would provide only average levels of diversification to a portfolio similar to the broader market.
- Over the last 90 days, MDXH shares have been more volatile than the overall market, as the stock's daily price fluctuations have exceeded that of 93% of BELGIUM 20 index firms.

RISK ANALYSIS

Peers	Last 90 Days			Last 60 Months		
	Best Daily Return	Worst Daily Return	# Days Up / # Days Down	Largest Intra-Day Swing	Best Monthly Return	Worst Monthly Return
<b>MDXH</b>	<b>5.0%</b>	<b>-5.6%</b>	<b>29 / 34</b>	<b>9.2%</b>	<b>25.4%</b>	<b>-21.2%</b>
ABLX	3.9%	-5.0%	31 / 32	8.3%	51.5%	-19.6%
ARGX	12.0%	-4.5%	36 / 23	10.8%	16.5%	-16.2%
CYAD	15.2%	-6.6%	36 / 27	18.0%	76.1%	-54.8%
THR	8.0%	-4.5%	27 / 36	9.4%	34.4%	-48.1%
<b>BEL 20</b>	<b>3.1%</b>	<b>-1.4%</b>	<b>35 / 27</b>	<b>1.8%</b>	<b>7.6%</b>	<b>-8.0%</b>





PRICE MOMENTUM




Currency in EUR

**NEGATIVE OUTLOOK:** Weak recent price performance or entering historically poor seasonal period.

Price Momentum Score Averages

Biotech & Med. Research Group:	6.4	Mid/Small Market Cap:	5.3
Pharma. & Med. Research Sector:	6.2	BEL 20 Index:	7.0

Price Momentum Score Trend (4-Week Moving Avg)



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
ARGX	8	6	7	2	9	
CYAD	4	3	8	8	9	
ABLX	3	7	1	2	5	
THR	4	8	1	4	3	
<b>MDXH</b>	<b>10</b>	<b>8</b>	<b>4</b>	<b>2</b>	<b>2</b>	

PRICE MOMENTUM INDICATORS

Relative Strength (70% weight)

Seasonality (30% weight)



Relative Strength Indicator (Scale from 1 to 100)

	MDXH	Industry Avg
Last 1 Month	42	55
Last 3 Months	49	54
Last 6 Months	51	53


Average Monthly Return (Last 10 Years)

	MAY	JUN	JUL
Company Avg	-1.0%	-4.3%	3.7%
Industry Avg	2.9%	-10.3%	4.9%
Industry Rank	1 of 5	6 of 6	2 of 6

PRICE PERFORMANCE

Daily close prices are used to calculate the performance of the stock as compared to a relevant index over five time periods.

MDXH  
BEL Small



	MDXH	BEL Small
Close Price (2017-05-19)	4.91	14,241
52-Week High	5.78	14,368
52-Week Low	2.87	11,238

- MDxHealth has a Price Momentum Rating of 2, which is significantly below the BELGIUM 20 index average rating of 7.5.
- On 2017-05-19, MDXH closed at 4.91, 15.0% below its 52-week high and 71.1% above its 52-week low.
- MDXH shares are currently trading 6.7% below their 50-day moving average of 5.26, and 3.5% above their 200-day moving average of 4.75.



## DETAILED STOCK REPORT TIPS

The Thomson Reuters Stock Report is a comprehensive, company-specific analysis that includes a proprietary Stock Rating along with underlying component indicators and supportive data elements. The report is updated daily, although some of the data elements and the ratings are updated weekly.

**Average Score**

The Average Score combines a quantitative analysis of five widely-used investment decision making tools - Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. First, a simple average of the five underlying component ratings is calculated. Then, a normal distribution is used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A score of 8 to 10 is considered positive, 4 to 7 is neutral, and 1 to 3 is negative. These five factors may be evaluated differently using alternative methodologies, and the importance of individual factors varies across industry groups, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.

A company must have sufficient data available for at least three of the five component indicators in order to receive an overall Average Score. Approximately 85% of the stocks within the coverage universe meet the criteria to generate a score.

**Indicator Components**

The five indicators that comprise the stock rating are displayed. Like the stock rating, the component rating scale is 1 to 10, with 10 being best. A company will receive an 'NR' for No Rating if the required data elements or criteria are not met. A detailed section for each component is included in the report.

**Indicator Trends**

Within each component section, historical score trends are displayed, typically using a 4-week moving average over a timeframe of the past three years. The dotted orange line indicates the average of the scores over those three years. The most recent occurrences of the best and worst scores are also displayed on the chart in grey boxes to put the current score into historical context.

Next to the trend chart for the company, current score averages are included, along with peer company comparisons of values from 6 months ago, 3 months ago, 1 month ago, the most recent value from 1 week ago, and the current score. The four closest industry peers are presented based on similar market capitalization.

**Peer Analysis**

The Thomson Reuters Business Classification (TRBC) system is used for industry comparisons. It is designed to track and display the primary business of a corporation by grouping together correlated companies that offer products and services into similar end markets. The system includes 10 Economic Sectors, 28 Business Sectors, 54 Industry Groups, and 136 Industries.

The Peer Analysis section of the report compares the company to its ten closest peers. The peers are selected from the industry based on similar market capitalization. The peer listing may have fewer than ten companies if there are fewer than ten companies within that industry classification.

**Highlights**

The Thomson Reuters proprietary automated text-generation system creates highlights summarizing the most noteworthy data. The bullets will vary by company and will change from week to week as different criteria are met.

**Earnings**

The Earnings Rating is based on a combination of three factors: earnings surprise, estimate revision, and recommendation changes. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least two of the three earnings factors in order to receive a score.

Earnings Surprises - The number of positive and negative surprises within the last 4 periods (quarters or years).

Estimate Revisions - The number of up and down revisions and the average percentage change of those revisions within a 4 week period.

Recommendation Changes - The number of broker upgrades and downgrades in the last 120 days.

**Price Target**

The price target is based on the predictions of analysts covering the stock and shows the high, low and mean price expected within the next 12 months.

**Earnings Per Share**

The quarterly and annual earnings per share are presented when available, along with the mean, high and low. Quarterly data is displayed for the past 4 quarters (actual) and the next 2 quarters (estimated). Annual data is displayed for the past 2 years (actual) and the next 2 years (estimated).

**Mean Estimate Trend**

The mean estimates show how the consensus has changed over the past 30 days and 90 days for the upcoming two quarters (when available) and two years. The percentage change is calculated for the company as a means for comparison by measuring the difference between the current consensus estimate and that of 90 days ago.

**Analyst Recommendations**

The I/B/E/S Mean is the mean recommendation of all analysts covering the stock, as provided by Thomson Reuters I/B/E/S (Institutional Brokers Estimate System). The recommendations are presented on a five-point standardized scale: strong buy, buy, hold, reduce, and sell.

**Earnings Surprises**

The surprise summary includes the total number of time periods (and percentage) in the last 12 quarters (quarterly) or last 4 years (annual) in which earnings surprises were positive, negative, or in-line. In order to be recognized as a positive or negative surprise, the percent must be greater than 2% above or 2% below the consensus, respectively.

The surprise detail section includes a listing of the company's quarterly earnings reported for the most recent 6 periods (quarters or years). The consensus analyst estimate is provided to determine if the actual earnings report represented a positive surprise, negative surprise, or in-line result.

**Fundamental**

The Fundamental Rating is based on a combination of four fundamental component factors: profitability, debt, earnings quality, and dividend. Companies that do not pay a dividend are not penalized. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least three of the four fundamental factors present in order to receive a score.

Profitability is comprised of four data elements.

- Revenue Growth: (Net Sales – Previous Net Sales) / Previous Net Sales
- Gross Margin: Gross Profit / Net Sales
- Return on Equity: Net Income / Total Equity
- Net Margin: Net Profit / Net Sales

Debt is comprised of four data elements.

- Current Ratio: Current Assets / Current Liabilities
  - Debt-to-Capital: Total Debt / Total Capital
  - Interest Funding: Interest Expense / Operating Cash Flow
  - Interest Coverage: (Pre-Tax Income + Interest Expense) / Interest Expense
- Earnings Quality is comprised of two data elements.
- Days Sales in Inventory: 365 / (Cost of Goods Sold / Inventory)
  - Days Sales in Receivables: 365 / (Net Sales (Revenues) / Receivables)

Dividend is comprised of four data elements. The company must have a current dividend yield.

- Dividend Growth Rate: (Dividends per Share – Previous Dividends per Share) / Previous Dividends per Share
- Dividend Funding: Dividends / Operating Cash Flow
- Dividend Coverage: (Pre-Tax Income + Interest Expense) / (Interest Expense + Dividends)
- Dividend Yield: Annual Dividends per Share / Current Market Price per Share

**Indicator Trend**

The fundamental indicator trend displays either quarterly scores over the past three years or annual scores over the past six years, depending on the reporting periods for the country. The best and worst scores can be easily determined from the values shown on the chart for each quarter or year.

**Relative Valuation**

The Relative Valuation Rating is based on a combination of three component factors: Price to Sales (50% weight), Trailing P/E (25% weight), and Forward P/E (25% weight). After the weightings are considered to combine individual factors, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. These common valuation metrics are evaluated against the overall market, the index, and the company's own historic 5-year averages. A stock needs to have at least one of the three relative valuation factors in order to receive a score.

Price to Sales: Close Price / (Sales for 4 Quarters or 1 Year / Shares Outstanding)

Trailing P/E: Close Price / Most Recent 4 Quarters or 1 Year of Earnings

Forward P/E: Close Price / Upcoming 4 Quarters or 1 Year of Earnings

**Valuation Averages**

Negative values are excluded when calculating the averages. A maximum value of 100 is placed on Trailing P/E and Forward P/E, a maximum value of 5 is placed on Forward PEG, and a maximum value of 20 is placed on Price to Sales when calculating the averages. Higher values are rounded down to the maximum for the averages.



**Valuation Multiples**

The valuation multiples provide the Trailing P/E, Forward P/E, Forward PEG, and Price to Sales for the company and the S&P 500 index average. In addition, a comparison of the current company's values to its 5-year average and an industry average are presented. A discount occurs when the company's ratio is valued more favorably (lower) than that to which it is compared.

**Risk**

The Risk Rating displays stocks on a scale of 1 to 10 with 10 being awarded to the least risky stocks. It is derived by looking at a series of long-term (5-year) and short-term (90-day) stock performance measures including volatility, magnitude of returns, beta, and correlation. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market. A stock needs to have at least two of the four risk factors in order to receive a score.

Magnitude of Returns – The best / worst daily returns in the past 90 days and the best / worst monthly returns in the past 60 months.

Volatility – The standard deviation of the stock price over the last 90 days and last 60 months, along with the average and largest intra-day stock swing.

Beta – Measures the tendency of a security's returns to respond to swings in the market, based on the beta of the company versus the relevant index.

Correlation – Determines how closely the returns of the stock and the relevant index move together, measured over the last 90 days and last 60 months.

**Risk Analysis**

Price analysis for the company and the relevant index is provided over two time periods. Daily analysis is provided for the last 90 days, whereas monthly statistics are used for the last 60 months.

**Price Momentum**

The Price Momentum Rating is based on a combination of two technical performance factors: relative strength (70% weight) and seasonality (30% weight). After the weightings are considered to combine individual factors, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have data for the relative strength factor in order to receive a score.

Relative Strength – The relative strength of the company for the last 1 month, 3 months, and 6 months on a scale of 1 to 100.

Seasonality – The average monthly return (price performance) for the current month and next 2 months for the company and industry, over the past 10 years. A lower industry rank indicates a higher return.

**Price Performance**

Daily close prices are used to calculate the price performance of the stock. The performance of the relevant index is also displayed as a means of comparison.

**DISCLAIMER**

Thomson Reuters content ("TR Content") is the intellectual property of Thomson Reuters or its third party content providers. The copying, republication or redistribution of TR Content, including by framing or similar means is expressly prohibited without the prior written consent of Thomson Reuters. The TR content in this report does not constitute a recommendation to buy or sell securities of any kind or constitute investment advice. Past performance is not a guarantee of future results.

All information in this report is assumed to be accurate to the best of our ability. Thomson Reuters excludes all liability, to the maximum extent permitted by law, for any inaccuracies in the TR Content or for the consequences of your reliance on the TR Content. Investors should consider this report as only a single factor when making an investment decision.

